UA67832C2 - СПОСІБ ОТРИМАННЯ [S-(R<sup>*</sup>,S<sup>*</sup>)]-<font face="Symbol">b</font>-[[[1-[1-ОКСО-3-(4-ПІПЕРИДИНІЛ)ПРОПІЛ]-3-ПІПЕРИДИНІЛ]КАРБОНІЛ]АМІНО]-3-ПІРИДИНПРОПАНОВОЇ КИСЛОТИ ТА ЇЇ ПОХІДНИХ - Google Patents

СПОСІБ ОТРИМАННЯ [S-(R<sup>*</sup>,S<sup>*</sup>)]-<font face="Symbol">b</font>-[[[1-[1-ОКСО-3-(4-ПІПЕРИДИНІЛ)ПРОПІЛ]-3-ПІПЕРИДИНІЛ]КАРБОНІЛ]АМІНО]-3-ПІРИДИНПРОПАНОВОЇ КИСЛОТИ ТА ЇЇ ПОХІДНИХ Download PDF

Info

Publication number
UA67832C2
UA67832C2 UA2001096538A UA200196538A UA67832C2 UA 67832 C2 UA67832 C2 UA 67832C2 UA 2001096538 A UA2001096538 A UA 2001096538A UA 200196538 A UA200196538 A UA 200196538A UA 67832 C2 UA67832 C2 UA 67832C2
Authority
UA
Ukraine
Prior art keywords
formula
compound
salt
differs
interaction
Prior art date
Application number
UA2001096538A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Юдит Х. КОХЕН
Міхаель Юстус
Цинтіа А. Меріанофф
Армін Росслер
Фрідтоф Хармен Шродер
Франк Джон Джр Віллані
Хрістіан Вен
Original Assignee
Орто-Макнейл Фармацевтикал, Інк.
Орто-Макнейл Фармацевтикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орто-Макнейл Фармацевтикал, Інк., Орто-Макнейл Фармацевтикал, Инк. filed Critical Орто-Макнейл Фармацевтикал, Інк.
Publication of UA67832C2 publication Critical patent/UA67832C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UA2001096538A 1999-03-22 2000-03-21 СПОСІБ ОТРИМАННЯ [S-(R<sup>*</sup>,S<sup>*</sup>)]-<font face="Symbol">b</font>-[[[1-[1-ОКСО-3-(4-ПІПЕРИДИНІЛ)ПРОПІЛ]-3-ПІПЕРИДИНІЛ]КАРБОНІЛ]АМІНО]-3-ПІРИДИНПРОПАНОВОЇ КИСЛОТИ ТА ЇЇ ПОХІДНИХ UA67832C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12567199P 1999-03-22 1999-03-22
PCT/US2000/007462 WO2000056730A1 (en) 1999-03-22 2000-03-21 PROCESS FOR PREPARING [S-(R*,S*)] -β -[[[1-[1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES

Publications (1)

Publication Number Publication Date
UA67832C2 true UA67832C2 (uk) 2004-07-15

Family

ID=22420863

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001096538A UA67832C2 (uk) 1999-03-22 2000-03-21 СПОСІБ ОТРИМАННЯ [S-(R<sup>*</sup>,S<sup>*</sup>)]-<font face="Symbol">b</font>-[[[1-[1-ОКСО-3-(4-ПІПЕРИДИНІЛ)ПРОПІЛ]-3-ПІПЕРИДИНІЛ]КАРБОНІЛ]АМІНО]-3-ПІРИДИНПРОПАНОВОЇ КИСЛОТИ ТА ЇЇ ПОХІДНИХ

Country Status (22)

Country Link
US (2) US6515130B1 (enExample)
EP (1) EP1165543B1 (enExample)
JP (1) JP2002540108A (enExample)
KR (1) KR20020019895A (enExample)
CN (1) CN1351600A (enExample)
AT (1) ATE242235T1 (enExample)
AU (1) AU775413B2 (enExample)
BR (1) BR0010652A (enExample)
CA (1) CA2368024A1 (enExample)
CZ (1) CZ20013431A3 (enExample)
DE (1) DE60003169T2 (enExample)
DK (1) DK1165543T3 (enExample)
ES (1) ES2199805T3 (enExample)
HK (1) HK1046272A1 (enExample)
HR (1) HRP20010767A2 (enExample)
HU (1) HUP0201262A3 (enExample)
MX (1) MXPA01009615A (enExample)
PT (1) PT1165543E (enExample)
SK (1) SK13562001A3 (enExample)
UA (1) UA67832C2 (enExample)
WO (1) WO2000056730A1 (enExample)
YU (1) YU74601A (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367971A1 (en) 1999-03-22 2000-09-28 Ortho-Mcneil Pharmaceutical, Inc. Synthesis of 3-amino-3-aryl propanoates
BR0212896A (pt) * 2001-09-21 2004-10-13 Sanofi Synthelabo Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4- ona e 7-piridinil-2,3dihidroimidazo[1,2-a] pirimidin-5(1h)ona substituìdos
HRP20170464T1 (hr) 2011-08-17 2017-05-19 Piramal Imaging Sa Spojevi za vezanje na glikoprotein iib/iiia specifičan za trombocite i njihova upotreba u vizualiziranju ugrušaka
EP2956461A1 (en) 2013-02-12 2015-12-23 Bayer Pharma Aktiengesellschaft Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia
EP2958894B8 (en) 2013-02-20 2020-02-26 Reuter Chemische Apparatenbau e.K. Process for the preparation of enantiomerically enriched 3-aminopiperidine
US20160068486A1 (en) 2013-04-22 2016-03-10 Reuter Chemische Apparatebau Kg Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine
KR102548998B1 (ko) 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58243B1 (en) 1983-12-07 1993-08-11 Lonza Ag A process for the preparation of optically-active 3-amino carboxylic acids
US5254573A (en) 1991-10-15 1993-10-19 Monsanto Company Substituted heterocyclic derivatives useful as platelet aggregation inhibitors
DE69429328T2 (de) 1993-09-22 2002-06-13 Fujisawa Pharmaceutical Co., Ltd. N-(3-piperidinylcarbonyl)-b-alanin derivate als paf-antagonisten
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
KR19990087694A (ko) * 1996-03-13 1999-12-27 후지야마 아키라 피브리노겐 수용체 길항제로서의 N-[(R)-1-{3-(4-피페리딜)프로피오닐-3-피페리딜카보닐]-2(S)-아세틸아미노-β-알라닌
ES2320316T3 (es) * 1996-05-01 2009-05-21 Ortho-Mcneil Pharmaceutical, Inc. Derivados carboxamida de pirrolidina, piperidina y hexahidroazepina utiles en el tratamiento de trastornos tromboticos.
US5840961A (en) 1996-07-12 1998-11-24 G. D. Searle & Co. Asymmetric synthesis of chiral beta-amiNo acids
US6066651A (en) * 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders

Also Published As

Publication number Publication date
ATE242235T1 (de) 2003-06-15
EP1165543A1 (en) 2002-01-02
CN1351600A (zh) 2002-05-29
CZ20013431A3 (cs) 2003-04-16
SK13562001A3 (sk) 2002-08-06
AU775413B2 (en) 2004-07-29
ES2199805T3 (es) 2004-03-01
HUP0201262A2 (en) 2002-08-28
US6515130B1 (en) 2003-02-04
MXPA01009615A (es) 2003-07-21
KR20020019895A (ko) 2002-03-13
YU74601A (sh) 2004-05-12
AU3766100A (en) 2000-10-09
US20020137937A1 (en) 2002-09-26
BR0010652A (pt) 2002-07-16
EP1165543B1 (en) 2003-06-04
DK1165543T3 (da) 2003-09-29
HUP0201262A3 (en) 2003-12-29
DE60003169T2 (de) 2005-10-27
PT1165543E (pt) 2003-10-31
HU0201262D0 (enExample) 2002-05-29
DE60003169D1 (de) 2003-07-10
WO2000056730A1 (en) 2000-09-28
HRP20010767A2 (en) 2002-12-31
JP2002540108A (ja) 2002-11-26
HK1046272A1 (zh) 2003-01-03
CA2368024A1 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
US5210266A (en) N-substituted mercaptopropanamide derivatives
US5179125A (en) N-substituted mercaptopropanamide derivatives
UA72768C2 (en) A method for obtaining amilodipine benzenesulphonate
JP7252978B2 (ja) 2-(1-(tert-ブトキシカルボニル)ピペリジン-4-イル)安息香酸を調製するためのプロセス
KR20190044652A (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
EP1165543B1 (en) PROCESS FOR PREPARING S-(R*,S*)] -$g(b) - 1- 1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES
US20240262805A1 (en) Method for producing compound or pharmaceutically acceptable salt thereof
US20110040097A1 (en) Process for preparing lercanidipine hydrochloride
KR20030050412A (ko) 레바미피드의 제조방법
JPS5833877B2 (ja) ユウキカゴウブツニカンスルカイリヨウ
EP3658569B1 (en) Process and intermediates for synthesis of peptide compounds
JPH078855B2 (ja) スルホニウム化合物
RU2157365C2 (ru) Nα-2-(4-НИТРОФЕНИЛСУЛЬФОНИЛ)ЭТОКСИКАРБОНИЛАМИНОКИСЛОТЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ)
JPH01290658A (ja) スルホニウム化合物の製造方法
CA2510773C (en) Crystalline form of quinapril hydrochloride and process for preparing the same
JP2004238322A (ja) (r)−3−アミノペンタンニトリルメタンスルホン酸塩の製造方法
JPH054987A (ja) ピラゾロピリジン誘導体の製造法
KR100821165B1 (ko) 레르카니디핀 염산염의 제조 방법
JPH01294690A (ja) α−アスパルチルフェニルアラニン誘導体の製造法
KR20020087091A (ko) 아미드 결합을 형성하는 방법
WO2019098551A1 (ko) 의약품 합성용 중간체 화합물의 제조 방법
JPH0193563A (ja) (2S,3R,4S)―α―(カルボキシシクロプロピル)グリシン及びその製造法
MXPA99005398A (en) Process for the preparation of nmda antagonists
CN111868031A (zh) N-烷氧基羰基哌啶衍生物的制备方法及其中间体
JPH0142936B2 (enExample)